ClinicalTrials.gg
RecruitingNCT07111936CONNECT-MLUpdated Aug 13, 2026

Evaluating the Impact of CONNECT in a Multilingual Population

An interventional study of CONNECT Intervention for multilingual populations and Saliva Sample in Smoking Cessation, Smoking Cessation Counseling Ability and Practice and Smoking Cessation Counselling, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
439
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Smoking Cessation by University of California, San Francisco — 5 open to participants now, 6 under way, none of them phase 3. Smoking Cessation · University of California, San Francisco.

Planned enrollment
9th of 38
439 · median 174
Started
2025
with 2 others
No phase
31 of 39
5 open now
Registered
37th of 39
by date

Among the 39 studies in Smoking Cessation by University of California, San Francisco, this one is the 9th largest by planned enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2025, is one of 31 with no phase, and was the 37th registered.

Smoking Cessation

1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

5 of the 39 studies in Smoking Cessation by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Smoking Cessation by University of California, San Francisco, or all of them as a file.
02

Study summary

This study aims to broaden the reach of the lung cancer screening (LCS) CONNECT program (NCT04149249, NCT06213532), by developing a version of the program to be available to multilingual communities. The CONNECT program encourages individuals who are undergoing lung cancer screening to also quit smoking by providing a personalized program which includes a video doctor with personalized responses, text message and telephone call support and connection with a pharmacist to assist in obtaining nicotine replacement medication. This clinical trial will develop and ultimately test how well the CONNECT Multilingual (CONNECT ML) program works to improve smoking cessation among current adult smokers within the Spanish and Cantonese speaking communities.

Read the detailed description

PRIMARY OBJECTIVES:

I. Culturally adapt, translate, improve and fine tune the multi-faceted CONNECT program for multilingual smokers

II. Evaluate the CONNECT multilingual program for current smokers in multilingual communities.

III. Assess the impact of the CONNECT Multilingual program on smoking cessation rates and participant utilization of evidence-based resources to help quit smoking

OUTLINE:

FOCUS GROUP (N=24):

Three focus groups, one each with English, Spanish and Cantonese speaking participants (8 in each group) will be led by investigators. Interviews will be recorded, transcribed and translated. Translation of the Spanish and Cantonese transcripts will be done by University of California, San Francisco (UCSF) translation services.

BETA GROUP (N=15):

The investigators will conduct a pilot, beta testing of the intervention materials with English, Spanish and Cantonese speaking participants. Additional feedback and input from the participants will be used to fine tune the CONNECT smoking cessation intervention to be implemented in a randomized trial.

RANDOMIZED CONTROLLED TRIAL (N=400):

Newly enrolled participants will be assigned to 1 of 2 conditions.

  • Group 1: Participants receive the CONNECT Multilingual intervention. Participants will be followed up at 1-week, 1-, 3-, and 6-months after treatment assignment. At 6-months, participants will be asked to complete and return an at-home saliva kit to verify their smoking status.
  • Group 2: Participants receive usual care from providers at a regular primary care appointment. Participants will be followed up at 1-week, 1-, 3-, and 6-months after treatment assignment.
03

Conditions studied

  • Smoking Cessation
  • Smoking Cessation Counseling Ability and Practice
  • Smoking Cessation Counselling
  • Lung Cancer Screening

Browse trials for

Keywords

  • Multilingual
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 50-80 years old.
  • Current smokers defined at smoking at least one cigarette in past 7 days AND eligible for lung cancer screening (LCS) based on smoking history (>=20 pack year history)
  • California (CA) residents
  • Able to understand and comply with study procedures for the entire length of the study.
  • Ability of individual or legal guardian/representative to understand a written document, and the willingness to sign it.

Exclusion criteria

Exclusion Criteria:

  • Non-smokers.
  • Individuals with a diagnosis of lung cancer.
  • Individuals receiving hospice care.
  • Individuals whose providers do not think that they should participate (e.g., psychiatric illness or significant cognitive impairment that would impede the individuals ability to participate).
  • Hearing and/or vision disabilities that would prevent participants from adequately receiving treatment components such as video or telephone counseling.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
439 participants (estimated)

Study arms

  • Other
    Focus Group

    Participants in the focus group will be interviewed by the study staff and discuss barriers and facilitators to smoking cessation to be implemented in the beta and randomized phases of the study.

    Other: Interview

  • Active comparator
    Beta Group

    Participants will be testing the CONNECT multilingual smoking cessation materials and provide feedback to investigators. Participation will be limited to about 1.5 - 2 hours.

    Behavioral: CONNECT Intervention for multilingual populations

  • Experimental
    Group 1: CONNECT Multi-lingual intervention

    Participants receive the CONNECT multilingual smoking cessation intervention finalized in the beta group analysis, that includes multi-lingual interactive video doctor intervention, text messages once weekly for 12 weeks, and several telephone counseling calls. Participants also receive access to a pharmacist to receive counseling about quitting smoking and may prescribe nicotine replacement therapy. Participants will be asked to provide a saliva sample at the end of the study

    Behavioral: CONNECT Intervention for multilingual populations · Other: Saliva Sample

  • Experimental
    Group 2: Control Group

    Participants will receive usual care for smoking cessation at routine medical visit and be asked to complete a total of four brief follow-up phone surveys. Participants will be asked to provide a saliva sample at the end of the study.

    Other: Saliva Sample

Interventions

  • BehavioralCONNECT Intervention for multilingual populations

    The program includes interactive Video Doctor visits to provide participants with information tailored to their individual responses and outreach via brief telephone calls and text messaging to follow-up and connect smokers with evidence-based resources for smoking cessation.

    Also known as: CONNECT Multilingual program

  • OtherSaliva Sample

    Undergo saliva collection

    Also known as: Saliva Sample collection

  • OtherInterview

    Attend a focus group

06

What researchers measure

Primary outcomes

  1. Percentage of participants Smoking cessation rates (Randomized groups only)

    The rate of smoking cessation will be defined as the percentage of participants who are abstinent from smoking through self-report and biochemical verification using salivary cotinine levels obtained at 6 months after lung cancer screening

    Time frame: Up to 6 months

  2. Mean number of quit attempts over time (Randomized groups only)

    The number of self-reported 7-day quit attempts over time since lung cancer screening (LCS) will be recorded. Mean and standard deviation will be reported.

    Time frame: Up to 6 months

  3. Percentage of participants who reported use of smoking cessation resources (Randomized groups only)

    Self-reported use of evidence-based smoking cessation resources (enabling factors) after the lung cancer screening (for example, pharmacotherapy for smoking cessation, calling the California Smokers Helpline, group or individual counseling from healthcare providers, etc.) will be reported as a percentage of all participants by arm.

    Time frame: Up to 6 months

Secondary outcomes

  1. Changes in frequency of response to "Are you seriously thinking of quitting smoking?" over time (Randomized groups only)

    The participants readiness to quit will be measured using the Stages of Change questionnaire - single item, which asks "Are you seriously thinking of quitting smoking?" Answers range from 'Yes, within the next 30 days', 'Yes, within the next 6 months', and 'No, not thinking of quitting'. Changes in frequency of response over time will be reported.

    Time frame: Up to 6 months

  2. Changes in scores on the Readiness and Motivation to Quit Smoking Questionnaire (RMQ) over time (Randomized groups only)

    The RMQ is a 11 item self-report, that is used to assess the degree to which measures a person may be ready or motivated to change smoking habits and behaviors. The questionnaire consists of 3 factors: Change smoking behavior (5 items), Motivation to cut down (4 items), and Confidence (2 items). Questions are responded to as Yes/No, or range from "Not at all" to "Very", or ask the duration of time before quitting smoking. The greater the number of positive responses indicates a greater readiness to quit, a greater motivation to quit, and/or a greater confidence to quit smoking.

    Time frame: Up to 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Mar 2028, 31 months after the start.

Of 547 non-industry interventional studies with no phase under Smoking Cessation, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 31 months is above that.

Counting every sponsor, half of 564 studies reached it within 24 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2025
First posted
Aug 8, 2025
StartActual
Aug 7, 2025
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2028
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07111936
Collaborators
Tobacco Related Disease Research Program
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Aug 7, 2025
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Aug 13, 2026

Study contacts

Anita Ponce, MSc
Contact
Anita.Ponce@ucsf.edu
415-502-1317
Judith Walsh, MD, MPH
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion